S&P 500 slips as weaker services data stoke fresh economic concerns
Mckesson (NYSE:MCK), a prominent player in the Healthcare Providers & Services industry with a market capitalization of $89.5 billion, saw its Chief Executive Officer Tyler S. Brian sell 19,371 shares of common stock on July 11, 2025, for $708.09 per share. The total value of the transaction amounted to $13,716,411. According to InvestingPro analysis, the stock is currently trading near its 52-week high, with an overall Financial Health score rated as GREAT.
Following the transaction, Tyler S. Brian directly owns 27,872 shares of the company. In addition, Tyler S. Brian indirectly owns 215.180 shares of common stock through the Mckesson Corporation 401(k) Retirement Savings Plan. The stock has demonstrated strong performance, trading at $715.57 with a P/E ratio of 27.65.
The sale was executed under a pre-arranged trading plan adopted on November 8, 2024, in accordance with Rule 10b5-1(c). For more detailed insights and 15 additional ProTips about Mckesson’s financial performance and outlook, visit InvestingPro, where you’ll find comprehensive analysis and valuation metrics in our Pro Research Report.
In other recent news, McKesson Corporation reported robust financial results for Q3 2025, with earnings per share (EPS) of $10.12, surpassing the forecast of $9.81, although revenue fell short at $90.82 billion against expectations of $93.48 billion. Jefferies analyst Rob Dickerson raised McKesson’s stock price target to $800, citing the company’s strong fourth-quarter performance and optimistic EPS guidance for fiscal year 2026. Additionally, McKesson completed the acquisition of a 70% controlling interest in Core Ventures for approximately $2.49 billion, aiming to enhance oncology care. Morgan Stanley (NYSE:MS) also raised its price target for McKesson to $770, maintaining an Overweight rating, and highlighted the company’s strategic divestment of its MedSurg business. Meanwhile, Wells Fargo (NYSE:WFC) maintained an Equal Weight rating on McKesson, with a price target of $766, following a slight increase in full-year EPS guidance. These developments reflect McKesson’s ongoing strategic focus on its core business areas and its efforts to improve profitability and investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.